Why Investors Loved Moderna's Q3 Results
Moderna's (NASDAQ: MRNA) primary focus right now is to hopefully win regulatory approvals or authorizations for coronavirus vaccine mRNA-1273 to make it to the market. In the meantime, though, the biotech also has a business to run.
That business was front and center when Moderna announced its third-quarter results before the market opened on Thursday. Here are the highlights from its Q3 update.
Image source: Getty Images.
Source Fool.com
